- Home
- BCTXZ vs SSBK Comparison
BCTXZ vs SSBK Comparison
Compare BCTXZ & SSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTXZ
- SSBK
- Stock Information
- Founded
- BCTXZ N/A
- SSBK 2007
- Country
- BCTXZ Canada
- SSBK United States
- Employees
- BCTXZ 12
- SSBK N/A
- Industry
- BCTXZ
- SSBK Commercial Banks
- Sector
- BCTXZ
- SSBK Finance
- Exchange
- BCTXZ Nasdaq
- SSBK Nasdaq
- Market Cap
- BCTXZ N/A
- SSBK N/A
- IPO Year
- BCTXZ N/A
- SSBK 2021
- Fundamental
- Price
- BCTXZ $0.94
- SSBK $35.33
- Analyst Decision
- BCTXZ
- SSBK Buy
- Analyst Count
- BCTXZ 0
- SSBK 1
- Target Price
- BCTXZ N/A
- SSBK $36.00
- AVG Volume (30 Days)
- BCTXZ N/A
- SSBK 41.4K
- Earning Date
- BCTXZ N/A
- SSBK 04-21-2025
- Dividend Yield
- BCTXZ N/A
- SSBK 1.01%
- EPS Growth
- BCTXZ N/A
- SSBK 6.02
- EPS
- BCTXZ N/A
- SSBK 3.80
- Revenue
- BCTXZ N/A
- SSBK $99,026,000.00
- Revenue This Year
- BCTXZ N/A
- SSBK $19.18
- Revenue Next Year
- BCTXZ N/A
- SSBK $7.05
- P/E Ratio
- BCTXZ N/A
- SSBK $9.35
- Revenue Growth
- BCTXZ N/A
- SSBK 18.43
- 52 Week Low
- BCTXZ N/A
- SSBK $24.86
- 52 Week High
- BCTXZ N/A
- SSBK $39.16
- Technical
- Relative Strength Index (RSI)
- BCTXZ N/A
- SSBK 61.96
- Support Level
- BCTXZ N/A
- SSBK $34.44
- Resistance Level
- BCTXZ N/A
- SSBK $35.86
- Average True Range (ATR)
- BCTXZ 0.00
- SSBK 0.73
- MACD
- BCTXZ 0.00
- SSBK 0.26
- Stochastic Oscillator
- BCTXZ 0.00
- SSBK 88.77
About BCTXZ BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.